[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"osteoarthritis-knee\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:osteoarthritis-knee":28},{"pageToken":4,"total":5,"offset":6,"count":7,"results":8},null,96,0,25,[9,43,69,95,121,153,182,208,231,260,282,314,342,369,388,411,431,453,478,499,517,541,568,593,611],{"id":10,"slug":11,"hasResults":12,"nctId":13,"briefTitle":14,"officialTitle":15,"acronym":16,"eligibilityCriteria":17,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":31,"lastUpdatePostDateStruct":32,"startDateStruct":35,"completionDateStruct":37,"leadSponsor":39,"locationsCount":42},"100642998","phase-2-a-chronic-pain-master-protocol-cpmp-a-study-of-ly4065967-in-participants-with-osteoarthritis-pain-100642998",false,"NCT07641517","A Chronic Pain Master Protocol (CPMP): A Study of LY4065967 in Participants With Osteoarthritis Pain","Randomized, Placebo-Controlled, Phase 2 Clinical Trial to Evaluate LY4065967 for the Treatment of Osteoarthritis","OA07","Inclusion Criteria:\n\n* Have presence of index knee pain for more than 12 weeks at screening\n* Have an x-ray supporting diagnosis of osteoarthritis according to the American College of Rheumatology with a Kellgren-Lawrence grade 2 to 4 radiographic classification of index knee\n* Have a body mass index ≤40 kilograms per meter squared (kg\u002Fm²) (inclusive)\n* Have stable glycemic control as indicated by a glycated hemoglobin (HbA1c) less than or equal to 10 at time of screening\n\nExclusion Criteria:\n\n* Are pregnant or breastfeeding\n* Have had a surgical procedure or therapeutic injection in the affected knee within 3 months prior to screening\n* Have presence of surgical hardware or other foreign body in the index knee\n* Have ongoing complex regional pain syndrome or other concurrent medical condition that could interfere with the evaluation of pain in the index knee.\n* Have had any joint replacement of the lower extremity, such as hip, knee or ankle, in the 6 months prior to screening\n* Have an abnormal blood pressure (BP) (systolic BP greater than 140 millimeters mercury (\\>140 mm Hg) and diastolic BP\\>90 mm Hg) at screening\n* Have history or current clinically significant cardiac disease, including arrhythmia, aortic aneurysm, heart failure, current electrolyte abnormalities, or any other conditions that could predispose to arrhythmia in the judgement of the investigator","ALL","40 Years",{"count":21,"type":22},150,"ESTIMATED","INTERVENTIONAL",[25],"PHASE2","The main purpose of this study is to test the safety and efficacy of study drug for the treatment of knee pain due to osteoarthritis (OA). This trial is part of the chronic pain master protocol H0P-MC-CPMP (NCT05986292), which is a protocol to accelerate the development of new treatments for chronic pain.",[28,29],"Osteoarthritis, Knee","Chronic Pain","RECRUITING","2026-08-20",{"date":33,"type":34},"2026-08-21","ACTUAL",{"date":36,"type":34},"2026-06-25",{"date":38,"type":22},"2027-04",{"name":40,"class":41},"Eli Lilly and Company","INDUSTRY",37,{"id":44,"slug":45,"hasResults":12,"nctId":46,"briefTitle":47,"officialTitle":48,"acronym":4,"eligibilityCriteria":49,"healthyVolunteers":12,"sex":18,"minAge":50,"maxAge":51,"enrollmentInfo":52,"targetDuration":4,"studyType":23,"phases":54,"briefSummary":56,"conditions":57,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":58,"lastUpdatePostDateStruct":59,"startDateStruct":61,"completionDateStruct":63,"leadSponsor":65,"locationsCount":68},"100584322","radio--ko-radiotherapy-for-knee-osteoarthritis-clinical-trial-100584322","NCT06887829","Radio- KO Radiotherapy for Knee Osteoarthritis Clinical Trial","The Randomized Clinical Trial of Low-Dose Radiotherapy for Knee Osteoarthritis","Inclusion Criteria:\n\n* • patient's primary care provider is at Mayo Clinic in Rochester, MN\n\n  * age 50-100 years\n  * ICOAP pain scale A1 at least moderate intensity or B6 at least moderate intensity\n  * diagnosed with primary knee OA ICD-10 codes M17.x\n\n    o You have not had recurrent episodes of sudden onset of warmth, redness, or swelling of the affected knee\n  * physical exam findings of medial or lateral joint line tenderness on palpation that is in the same location as the knee pain.\n  * absence of primary knee pain in the pes anserine or hamstring or gastrocnemius, quadriceps, or patellar tendons on exam.\n  * radiographic Kellgren-Lawrence grade 2-3 on 4-view knee x-rays taken within the last year ability to complete surveys electronically by email\n\nExclusion Criteria:\n\n* • Kellgren-Lawrence grade 1 or 4\n\n  * pregnancy or women 54 years and younger with potential for pregnancy (if they or their partner have not had tubal ligation, hysterectomy, or vasectomy)\n  * history of ipsilateral intraarticular knee surgery\n  * use of injected corticosteroids within 3 months or hyaluronans within 6 months or within 1 month if there was no sustained improvement post-injection of either corticosteroid or hyaluronan.\n  * history of trauma to this knee in the last year that clearly caused the pain now present\n  * history of RA, gout, pseudogout, hemarthroses (eg, hemophilic arthropathy) or other inflammatory arthritis involving this knee\n  * history of symptomatic hip OA\n  * history of psychosis, personality disorder, uncontrolled affective disorder\n  * history of fibromyalgia\n  * malignancy requiring active treatment current regular use of opiate analgesics, PRP, or acupuncture for the knees","50 Years","100 Years",{"count":53,"type":22},128,[55],"NA","The primary aim of this study is to investigate whether low-dose radiotherapy is an effective treatment to reduce the pain of knee osteoarthritis. A secondary aim is to determine whether patients experience any more measurable side effects than those receiving sham treatments.",[28],"2026-08-17",{"date":60,"type":34},"2026-08-19",{"date":62,"type":34},"2025-06-04",{"date":64,"type":22},"2027-10-29",{"name":66,"class":67},"Mayo Clinic","OTHER",1,{"id":70,"slug":71,"hasResults":12,"nctId":72,"briefTitle":73,"officialTitle":74,"acronym":75,"eligibilityCriteria":76,"healthyVolunteers":12,"sex":18,"minAge":77,"maxAge":4,"enrollmentInfo":78,"targetDuration":4,"studyType":23,"phases":80,"briefSummary":82,"conditions":83,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":86,"lastUpdatePostDateStruct":87,"startDateStruct":88,"completionDateStruct":90,"leadSponsor":92,"locationsCount":94},"100632101","phase-3-amaze-6-a-research-study-investigating-how-well-the-medicine-nnc0487-0111-helps-people-with-excess-body-weight-and-knee-osteoarthritis-lose-weight-and-reduce-pain-100632101","NCT07509307","AMAZE 6: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight and Knee Osteoarthritis Lose Weight and Reduce Pain","Efficacy and Safety of NNC0487-0111 s.c. Once-weekly in Participants With Overweight or Obesity, and Knee Osteoarthritis (AMAZE 6)","AMAZE 6","Key Inclusion Criteria:\n\n* Male or female (sex at birth)\n* Age 18 years or above at the time of signing the informed consent\n* Clinical diagnosis of knee osteoarthritis (OA) (American College of Rheumatology criteria) with radiographic changes (Kellgren Lawrence \\[KL\\] grades 2 to 4 as per central reading) in target knee. Target knee joint is defined as most symptomatic knee at screening. If pain in knees is equal, the target knee joint will be the dominant leg\n* Symptomatic knee OA with first appearance of pain in the target knee \\> 90 days prior to screening and pain in the target knee for \\> 15 days over the prior 30 days\n* Willingness to complete a 72-hour washout period of analgesics before all visits involving WOMAC Osteoarthritis Index NRS 3.1 (24-hour) (WOMAC) questionnaire (acetaminophen 4 grams (g)\u002Fday is allowed as rescue medication up until 24 hours before those visits)\n\nKey Exclusion Criteria:\n\n* Glycated haemoglobin (HbA1c) ≥ 6.5% (48 mmol\u002Fmol) as measured by the central laboratory at screening\n* History of type 1 or type 2 diabetes mellitus as declared by the participant or reported in the medical records\n* Treatment with glucagon-like-peptide-1 (GLP-1) receptor agonists (RA), dual GLP-1\u002Fgastric inhibitory peptide (GIP) RAs (or any other GLP-1 based treatment), or amylin analogues before screening\n* Any joint prosthesis or joint replacement in target knee\n* Arthroscopy or injections into target knee within the last 90 days prior to screening\n* Any other joint disease in target knee including gout and pseudogout","18 Years",{"count":79,"type":22},400,[81],"PHASE3","This study is being done to look at the safety and effect of NNC0487-0111 in people with excess body weight and knee osteoarthritis when compared to placebo. There are 2 study treatments in this study taken as injections under the skin once a week. Participants will either get NNC0487-0111, (the treatment being tested) or Placebo (a treatment that has no active medicine in it). Which treatment participants get is decided by chance.",[84,85,28],"Obesity","Overweight","2026-08-14",{"date":58,"type":34},{"date":89,"type":34},"2026-04-20",{"date":91,"type":22},"2028-08-14",{"name":93,"class":41},"Novo Nordisk A\u002FS",81,{"id":96,"slug":97,"hasResults":12,"nctId":98,"briefTitle":99,"officialTitle":99,"acronym":4,"eligibilityCriteria":100,"healthyVolunteers":12,"sex":18,"minAge":77,"maxAge":101,"enrollmentInfo":102,"targetDuration":4,"studyType":23,"phases":104,"briefSummary":105,"conditions":106,"keywords":107,"overallStatus":112,"whyStopped":4,"lastUpdateSubmitDate":113,"lastUpdatePostDateStruct":114,"startDateStruct":115,"completionDateStruct":117,"leadSponsor":119,"locationsCount":68},"100651764","effect-of-nonsteroidal-anti-inflammatory-drug-restriction-on-the-efficacy-of-platelet-rich-plasma-in-knee-osteoarthritis-100651764","NCT07766330","Effect of Nonsteroidal Anti-Inflammatory Drug Restriction on the Efficacy of Platelet-Rich Plasma in Knee Osteoarthritis","Inclusion Criteria:\n\n* Age between 18 and 80 years\n* Knee pain for at least 3 months\n* Radiographic evidence of knee osteoarthritis classified as Kellgren-Lawrence grade I, II, or III\n* Ability and willingness to provide written informed consent\n\nExclusion Criteria:\n\n* Body mass index of 35 kg\u002Fm2 or higher\n* Pregnancy or breastfeeding\n* Diabetes mellitus with glycated hemoglobin greater than 6.5%\n* Hematologic disease, including anemia, coagulopathy, or thrombophilia\n* Hemoglobin below 11 g\u002FdL\n* Hematocrit below 33%\n* Platelet count below 150,000\u002Fmm3\n* Advanced knee osteoarthritis\n* Rheumatologic disease\n* Chronic kidney disease\n* Respiratory disease, including rhinitis, asthma, or chronic obstructive pulmonary disease\n* Active or previous oncologic disease, as defined in the protocol\n* Fibromyalgia\n* Psychiatric disorder currently under treatment\n* Substance dependence, including smoking, harmful alcohol use, or other substance use\n* Use of nonsteroidal anti-inflammatory drugs within the previous 30 days\n* Use of systemic, intra-articular, topical, or inhaled glucocorticoids within the previous 3 months\n* Current use of anticoagulant or antiplatelet medication\n* American Society of Anesthesiologists physical status classification of 3 or higher\n* Currently receiving disability or sickness-related social security benefits\n* Inability or unwillingness to provide informed consent or complete the required patient-reported outcome measures","80 Years",{"count":103,"type":22},90,[55],"The goal of this randomized clinical trial is to learn whether taking ibuprofen, a nonsteroidal anti-inflammatory drug, after a platelet-rich plasma (PRP) injection changes pain relief and knee function in adults with knee osteoarthritis.\n\nThe main questions it aims to answer are:\n\nDoes ibuprofen change the improvement in knee pain six months after a PRP injection compared with acetaminophen?\n\nDoes ibuprofen change knee function or the need for additional pain medicine during follow-up?\n\nResearchers will compare PRP followed by ibuprofen with PRP followed by acetaminophen. Participants will receive one ultrasound-guided PRP injection and take the assigned medication every eight hours for five days. They will complete assessments of pain, knee function, additional pain medicine use, and safety. Participants and the physician performing the injection will not know which medication was assigned.",[28],[108,109,110,111],"Platelet-Rich Plasma","Nonsteroidal Anti-Inflammatory Drugs","Intra-Articular Injection","Knee Pain","NOT_YET_RECRUITING","2026-08-11",{"date":86,"type":34},{"date":116,"type":22},"2026-10-01",{"date":118,"type":22},"2028-10",{"name":120,"class":67},"Federal University of São Paulo",{"id":122,"slug":123,"hasResults":12,"nctId":124,"briefTitle":125,"officialTitle":126,"acronym":127,"eligibilityCriteria":128,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":101,"enrollmentInfo":129,"targetDuration":4,"studyType":23,"phases":131,"briefSummary":133,"conditions":134,"keywords":137,"overallStatus":112,"whyStopped":4,"lastUpdateSubmitDate":145,"lastUpdatePostDateStruct":146,"startDateStruct":147,"completionDateStruct":149,"leadSponsor":151,"locationsCount":4},"100651260","phase-1-pre-emptive-insulin-to-prevent-high-glucose-after-a-knee-steroid-injection-in-adults-with-type-2-diabetes-100651260","NCT07757464","Pre-emptive Insulin to Prevent High Glucose After a Knee Steroid Injection in Adults With Type 2 Diabetes","A Phase 2 Randomized Trial of Pre-emptive NPH Insulin Versus Usual Reactive Diabetes Management for Preventing Hyperglycaemia After Intra-articular Triamcinolone Acetonide Injection in Adults With Type 2 Diabetes and Knee Osteoarthritis","PREVENT-SIH","Inclusion Criteria:\n\n* Age 40 to 80 years at consent.\n* Documented diagnosis of type 2 diabetes for at least 6 months.\n* HbA1c from 6.5% through 9.0% measured within 30 days before randomisation.\n* Symptomatic osteoarthritis of one knee for which the treating clinician has independently determined that an intra-articular corticosteroid injection is clinically indicated.\n* Planned administration of one intra-articular injection of triamcinolone acetonide crystalline suspension 40 mg into the index knee.\n* Diabetes managed without insulin, sulfonylureas or meglitinides.\n* Permitted glucose-lowering medications at stable doses for at least 30 days before randomisation.\n* Estimated glomerular filtration rate at least 45 mL\u002Fmin\u002F1.73 m² within 60 days before randomisation.\n* Capillary glucose from 90 through 250 mg\u002FdL immediately before the injection.\n* Ability and willingness to perform scheduled capillary glucose testing, administer or receive subcutaneous insulin if assigned, follow hypoglycaemia instructions and remain contactable through day 7.\n* Ability to wear the study continuous glucose monitoring device and provide informed consent.\n\nExclusion Criteria:\n\n* Type 1 diabetes, latent autoimmune diabetes in adults, pancreatogenic diabetes or another specific diabetes type requiring insulin.\n* Current basal, prandial, premixed or pump insulin treatment.\n* Current sulfonylurea or meglitinide treatment.\n* HbA1c below 6.5% or above 9.0%.\n* Capillary glucose below 90 mg\u002FdL or above 250 mg\u002FdL immediately before injection.\n* Fasting glucose above 250 mg\u002FdL, random glucose above 300 mg\u002FdL, clinically significant ketonaemia or hyperglycaemia requiring immediate treatment during screening.\n* Estimated glomerular filtration rate below 45 mL\u002Fmin\u002F1.73 m².\n* Severe hepatic impairment or another condition expected to materially alter insulin clearance or hypoglycaemia risk.\n* Level 3 hypoglycaemia requiring third-party assistance during the previous 6 months.\n* Documented impaired awareness of hypoglycaemia.\n* Pregnancy, planned pregnancy during study participation or breastfeeding.\n* Oral, intravenous or intramuscular corticosteroid use within 30 days before the study injection.\n* Any intra-articular, epidural, periarticular or soft-tissue corticosteroid injection within 30 days before the study injection.\n* Planned additional systemic or injected corticosteroid exposure before the day-7 assessment.\n* Acute febrile illness, active systemic infection or acute deterioration in health at screening or injection.\n* Suspected septic arthritis, infection over the injection site, prosthetic index knee, uncontrolled bleeding disorder or another contraindication to knee injection.\n* Known allergy or clinically significant hypersensitivity to triamcinolone acetonide, human NPH insulin, insulin aspart, protamine, lidocaine or required excipients.\n* Known allergy to continuous glucose monitoring adhesive or a skin condition preventing sensor use.\n* Cognitive, visual, physical or social limitation that would prevent safe glucose testing, insulin administration, hypoglycaemia treatment or study contact.\n* Participation in another interventional study likely to affect glucose or corticosteroid response.\n* Any condition that, in the investigator's documented judgement, makes participation unsafe for a reason not otherwise captured above.",{"count":130,"type":22},125,[132,25],"PHASE1","Steroid injections used to treat painful joints can temporarily increase glucose levels in people with type 2 diabetes. This study will test whether a short course of pre-emptive neutral protamine Hagedorn, NPH, insulin can reduce high glucose after a standard corticosteroid injection into the knee.\n\nAdults with type 2 diabetes who are scheduled to receive one intra-articular injection of triamcinolone acetonide 40 mg for knee osteoarthritis will be randomly assigned to one of two groups. The experimental group will receive a prespecified NPH insulin regimen beginning immediately after the injection and continuing for three doses. The comparison group will continue usual reactive diabetes management without pre-emptive NPH insulin.\n\nBoth groups will use blinded continuous glucose monitoring and scheduled capillary glucose testing. The main outcome is the percentage of continuous glucose monitoring time above 180 mg\u002FdL during the first 72 hours after the corticosteroid injection. Hypoglycaemia, rescue treatment, healthcare contacts, treatment burden, acceptability and adverse events will also be assessed.",[135,136,28],"Diabetes Mellitus, Type 2","Hyperglycemia Due to Type 2 Diabetes Mellitus",[138,139,140,141,142,143,144],"Steroid-induced hyperglycaemia","Glucocorticoid-induced hyperglycaemia","Intra-articular corticosteroid injection","Triamcinolone acetonide","NPH insulin","Continuous glucose monitoring","Knee osteoarthritis","2026-08-05",{"date":113,"type":34},{"date":148,"type":22},"2026-08-10",{"date":150,"type":22},"2027-01-30",{"name":152,"class":67},"Shifa International Hospital",{"id":154,"slug":155,"hasResults":12,"nctId":156,"briefTitle":157,"officialTitle":158,"acronym":4,"eligibilityCriteria":159,"healthyVolunteers":12,"sex":18,"minAge":77,"maxAge":4,"enrollmentInfo":160,"targetDuration":4,"studyType":23,"phases":162,"briefSummary":163,"conditions":164,"keywords":167,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":173,"lastUpdatePostDateStruct":174,"startDateStruct":176,"completionDateStruct":178,"leadSponsor":180,"locationsCount":68},"100633907","feasibility-of-good-boost-for-adults-awaiting-total-knee-replacement-100633907","NCT07532785","Feasibility of Good Boost+ for Adults Awaiting Total Knee Replacement","Feasibility of a Community-Based Aquatic Exercise and Peer Support Intervention (Good Boost+) for Adults on Knee Replacement Waiting Lists: A Randomised Hybrid Type 1 Effectiveness-Implementation Feasibility Trial","Inclusion Criteria:\n\nAged 18 years or over. Registered on a wait list for primary total knee replacement with sufficient time to complete the 6 week intervention and follow up assessments prior to surgery.\n\nModerate self reported intensity knee joint pain within the previous month, defined as ≥4 but \\\u003C10 on the 11 point Numeric Pain Rating Scale (NPRS: 0 = no pain, 10 = worst pain imaginable).\n\nWilling and able to participate in a six week programme of weekly group water-based exercise at specified leisure centre swimming pools in Southwark and three times weekly land-based exercise training in a private setting.\n\nWilling to pay £4.30 for water-based exercise sessions 5 \\& 6. This fee is in line with the usual cost of over 60s group exercise classes at local leisure centres.\n\nAccess to a smart phone or tablet computer with internet access. Willing and able to accept either trial arm allocation. Willing and able to give informed consent.\n\nExclusion Criteria:\n\nIndividuals scheduled to have another major joint replacement (e.g. contralateral knee, hip or shoulder) within the study period.\n\nIndividuals on the waiting list for revision surgery of a previous knee replacement.\n\nIndividuals with active inflammatory arthritis (e.g., RA, PsA, lupus, axial SpA) that is clinically symptomatic or requires ongoing immunosuppressive therapy to control disease activity.\n\nIndividuals who self-report being advised by a healthcare professional not to exercise.\n\nIndividuals who have previously participated in water-based exercise sessions delivered via the Good Boost HUB application.\n\nParticipating or planning to participate in another interventional clinical study\u002Ftrial during the study period that in the opinion of the investigator could affect the outcomes of this study.\n\nIndividuals unable to understand written or spoken English or communicate sufficiently well in English to participate despite assistance from a family member or friend.\n\nIndividuals unable to comply with the protocol \u002F requirements of study participation.\n\nIndividuals with any other severe concomitant disease that, in the opinion of the investigator might interfere with trial procedures and\u002For assessments.",{"count":161,"type":22},48,[55],"The goal of this randomised controlled feasibility trial is to find out whether it is possible to run a larger study of the Good Boost+ community based rehabilitation programme for people waiting for a primary total knee replacement.\n\nThe study will look at how many people are willing to take part, whether they stay in the study, and whether they can follow the Good Boost+ programme as planned. It will also explore how acceptable the programme is to patients, NHS staff and leisure centre staff, and which outcome measures are most useful for a future full scale trial. The study will also look at what helps or hinders delivery of the programme in real world NHS and community settings.\n\nThe main questions it aims to answer are:\n\n* How many people waiting for knee replacement surgery are willing to take part in the study\n* Whether participants can continue with the Good Boost+ programme as planned over the study period\n* Which outcome measures best capture any potential benefits of the programme\n* How acceptable the programme is to patients, NHS and leisure centre staff\n* What helps or makes it difficult to deliver the programme in practice.\n\nParticipants will be randomly assigned to one of two groups.\n\n* Usual NHS care or\n* Usual NHS care plus the Good Boost+ programme\n\nParticipants in the Good Boost+ programme will take part in six weekly group water based exercise sessions held in local swimming pools, as well as land based exercise sessions that can be done individually or by joining a virtual group. The exercise sessions are delivered through Good Boost's digital technology, using small waterproof tablet computers at swimming pools, and smartphones or computers for land-based sessions. Physiotherapy staff will provide guidance throughout, and volunteers will offer refreshments after pool sessions to support social connection.\n\nAll participants, including those receiving usual NHS care only, will be asked to complete an exercise diary, rate their knee pain each week, and complete short questionnaires at 6 and 10 weeks after joining the study.",[165,166],"Osteoarthritis (Knee)","Arthroplasties, Knee Replacement",[168,169,170,171,172],"Total Knee Replacement","Prehabilitation","Feasibility","Randomised controlled trial","Implementation","2026-08-04",{"date":175,"type":34},"2026-08-07",{"date":177,"type":22},"2026-08",{"date":179,"type":22},"2028-02",{"name":181,"class":67},"King's College Hospital NHS Trust",{"id":183,"slug":184,"hasResults":12,"nctId":185,"briefTitle":186,"officialTitle":187,"acronym":188,"eligibilityCriteria":189,"healthyVolunteers":12,"sex":18,"minAge":77,"maxAge":4,"enrollmentInfo":190,"targetDuration":4,"studyType":23,"phases":192,"briefSummary":193,"conditions":194,"keywords":195,"overallStatus":112,"whyStopped":4,"lastUpdateSubmitDate":198,"lastUpdatePostDateStruct":199,"startDateStruct":201,"completionDateStruct":203,"leadSponsor":205,"locationsCount":68},"100609834","boosting-exercise-adherence-in-knee-osteoarthritis-100609834","NCT07219732","Boosting Exercise Adherence in Knee Osteoarthritis","Boosting Exercise Adherence in Knee Osteoarthritis (BOOST-OA)","BOOST-OA","Inclusion Criteria:\n\n1. Diagnosis of knee OA (verified from the EHR)\n2. Knee pain for 3 months\n3. Knee pain on most days of the previous month,\n4. Average knee pain 3 (on a scale of 0-10),\n5. Self-report of some difficulty with walking or stair climbing.\n\nExclusion Criteria:\n\n1. Systemic rheumatic conditions, fibromyalgia, gout (knee)\n2. Dementia, psychosis or active substance abuse disorder\n3. Meniscus or knee ligament tear in the past 6 months\n4. Lower extremity surgery in past 6 months or planned in next 9 months\n5. Severe hearing or visual impairment\n6. Serious \u002F terminal illness\n7. Hospitalization for a cardiovascular event, past 3 months\n8. Unstable angina\n9. History of ventricular tachycardia\n10. Unstable chronic obstructive pulmonary disease\n11. Uncontrolled hypertension (diastolic \\>110 mm\u002FHg or systolic \\> 200mm\u002FHg)\n12. Stroke with moderate to severe aphasia\n13. History of three or more falls in past 6 months\n14. Resident of a long-term care facility\n15. Other health problem that would prohibit safe participation in the study or home exercise\n16. Current participation in another OA intervention study\n17. Currently meeting Department of Health and Human Services physical activity recommendations\n18. Completed PT for knee OA in the past year\n19. Unable to speak sufficient English to participate in study activities",{"count":191,"type":22},360,[55],"This project, conducted within the Department of Veterans Affairs Healthcare System (VHA), will test the effectiveness of an intervention to improve adherence to home exercise among Veterans receiving physical therapy (PT) for knee osteoarthritis (OA). The intervention, \"Boosting Exercise Adherence in Knee Osteoarthritis\" (BOOST-OA), has two phases. During the initiation phase (first 3 months of PT care), patients will receive tools and activities to address outcome expectations, action self-efficacy, goal-setting and monitoring. During the behavior maintenance phase (starting after PT care and continuing for 9 months), patients will receive health coaching calls that address satisfaction with outcomes, relapse prevention planning and independent monitoring. There are three main study aims: (1) examine improvements in patient outcomes, such as physical function, following BOOST-OA; (2) explore patient characteristics that lead to difference in reported improvements; and (3) interview participants and clinicians about their experience with BOOST-OA to inform future implementation.",[28],[196,197],"exercise, physical","physical therapy, health behavior","2026-07-21",{"date":200,"type":34},"2026-07-23",{"date":202,"type":22},"2026-09-14",{"date":204,"type":22},"2030-12-31",{"name":206,"class":207},"VA Office of Research and Development","FED",{"id":209,"slug":210,"hasResults":12,"nctId":211,"briefTitle":212,"officialTitle":212,"acronym":213,"eligibilityCriteria":214,"healthyVolunteers":215,"sex":216,"minAge":50,"maxAge":4,"enrollmentInfo":217,"targetDuration":4,"studyType":23,"phases":219,"briefSummary":220,"conditions":221,"keywords":222,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":198,"lastUpdatePostDateStruct":223,"startDateStruct":224,"completionDateStruct":226,"leadSponsor":228,"locationsCount":230},"100511945","the-osteoarthritis-prevention-study-100511945","NCT05946044","The Osteoarthritis Prevention Study","TOPS","Inclusion Criteria:\n\n* Female\n* BMI ≥ 30 kg\u002Fm2\n* An eligible knee will have no OA by xray and MRI\n* No or infrequent knee pain (\\\u003C 15 days\u002Fmonth) in the same knee\n\nExclusion Criteria:\n\n* symptomatic or severe coronary artery disease\n* unable to walk without a device\n* blindness\n* type 1 diabetes\n* active treatment for cancer\n* during the past 12 months knee fracture, anterior cruciate ligament (ACL), medial collateral ligament (MCL), or meniscus injury with or without surgical repair\n* knee injection during the past 6 months\n* bilateral knee OA by x-ray Kellgren-Lawrence (KL) ≥ 2\n* bilateral knee OA by MRI\n* bilateral symptomatic knee OA (frequent bilateral knee pain \\> 15 days per month)\n* BMI\\\u003C 30.0 kg\u002Fm2\n* male sex\n* claustrophobia\n* contraindication to MRI including body weight \\> 300 lbs or knee coil does not fit\n* unwillingness or inability to change eating and physical activity habits due to environment\n* cannot speak and read English\n* planning to leave area \\> 2 months during the 48-month intervention period",true,"FEMALE",{"count":218,"type":22},1230,[55],"The goal of this study is to establish the efficacy of an intervention of dietary weight loss, exercise, and weight-loss maintenance for knee Osteoarthritis (OA) prevention in adult females aged ≥ 50 years with obesity and no or infrequent knee pain. The primary aim is to compare the effects of a dietary weight loss, exercise, and weight-loss maintenance to an attention control group in preventing the development of structural Magnetic Resonance Imaging (MRI) knee OA. Secondary aims will determine the intervention effects on pain, mobility, health-related quality of life, knee joint compressive forces, inflammatory measures, weight loss, exercise self-efficacy, and cost-effectiveness of this intervention.",[28],[84,111],{"date":200,"type":34},{"date":225,"type":34},"2024-03-21",{"date":227,"type":22},"2029-07-31",{"name":229,"class":67},"Wake Forest University",4,{"id":232,"slug":233,"hasResults":12,"nctId":234,"briefTitle":235,"officialTitle":236,"acronym":237,"eligibilityCriteria":238,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":239,"targetDuration":4,"studyType":23,"phases":241,"briefSummary":242,"conditions":243,"keywords":244,"overallStatus":112,"whyStopped":4,"lastUpdateSubmitDate":252,"lastUpdatePostDateStruct":253,"startDateStruct":254,"completionDateStruct":256,"leadSponsor":258,"locationsCount":4},"100648083","robotic-assisted-versus-conventional-total-knee-arthroplasty-with-virtual-home-based-rehabilitation-100648083","NCT07716267","Robotic-Assisted Versus Conventional Total Knee Arthroplasty With Virtual Home-Based Rehabilitation","Evaluation Of Robotic-Assisted Versus Conventional Total Knee Arthroplasty Within A Virtual Peri-Operative Comprehensive Care Program: A Protocol For A Randomized Controlled Trial Assessing Knee-related Pain and Functional Limitation","R-TKR VCare","Inclusion Criteria:\n\n* Adults aged 40 years or older.\n* Knee osteoarthritis confirmed by clinical assessment and imaging (e.g., X-ray or MRI) requiring primary total knee replacement surgery.\n* Scheduled to undergo primary total knee arthroplasty with one of the participating surgeons at St John of God Murdoch Hospital.\n* Able to understand the study requirements and provide written informed consent.\n* Physically able to participate in the home-based exercise and stationary cycling rehabilitation program.\n\nExclusion Criteria:\n\n* Unable to understand English sufficiently to provide informed consent, complete study questionnaires, or safely follow the rehabilitation program.\n* Previous major surgery on the leg undergoing knee replacement (for example, revision knee replacement or high tibial osteotomy).\n* Osteoarthritis caused by another medical condition (for example, inflammatory arthritis, previous joint infection, gout, fracture involving the joint, congenital abnormality, or haemochromatosis).\n* Chronic pain unrelated to the knee being replaced that could affect study assessments.\n* Unstable heart or lung conditions that make exercise-based rehabilitation unsafe.\n* Body weight greater than 120 kg.\n* Physical conditions that prevent safe participation in the cycling-based rehabilitation program or completion of the study assessments.",{"count":240,"type":22},60,[55],"The goal of this clinical trial is to learn whether robotic-assisted total knee replacement improves recovery compared with conventional total knee replacement in adults with knee osteoarthritis when both groups follow the same structured home-based rehabilitation program. Robotic-assisted and conventional (non-robotic) total knee replacement are both widely used as part of routine clinical care. This study will compare recovery during the first six weeks after surgery.\n\nThe main questions the study aims to answer are:\n\n1. Does robotic-assisted total knee replacement improve knee pain and knee function six weeks after surgery compared with conventional total knee replacement?\n2. Does robotic-assisted surgery improve physical function, walking ability, leg strength, quality of life, and participants' experience of rehabilitation?\n3. Are there any differences in recovery, length of hospital stay, or safety between the two surgical approaches?\n\nResearchers will compare robotic-assisted total knee replacement with conventional total knee replacement. Both groups will complete the same rehabilitation program before and after surgery so that any differences in recovery are more likely to be related to the type of surgery rather than differences in rehabilitation.\n\nParticipants will:\n\n* Be randomly assigned (by chance, similar to flipping a coin) to receive either robotic-assisted or conventional total knee replacement surgery.\n* Complete a structured rehabilitation program that includes education and exercises during the four weeks before surgery and a home-based exercise program for six weeks after surgery.\n* Use a study-provided seated exercise bike, receive support from a physiotherapist through telehealth appointments, secure messaging, and home visits where required, and use a digital application to guide the rehabilitation program and record exercise completion and symptoms.\n* Complete questionnaires about knee pain, knee function, general health, quality of life, and satisfaction with the rehabilitation program.\n* Attend study assessments before surgery, immediately before surgery after completing the pre-surgery program, and about six weeks after surgery. These assessments include simple physical activities such as standing up from a chair, walking, cycling, and measuring leg strength.\n* Allow information about their surgery and hospital stay, such as the duration of surgery and the number of nights spent in hospital, to be recorded for the study.\n\nThe results of this study will help researchers understand whether robotic-assisted total knee replacement provides additional benefits over conventional total knee replacement when both are combined with the same structured home-based rehabilitation program. The findings may help patients, healthcare professionals, and health services make informed decisions about the use of robotic-assisted knee replacement surgery.",[28],[245,246,247,248,249,250,251],"Arthroplasty, Replacement, Knee","Robotic-Assisted Total Knee Arthroplasty","Home-Based Rehabilitation","Telerehabilitation","Recovery of Function","Inertial Measurement Units","Force Plates","2026-07-16",{"date":198,"type":34},{"date":255,"type":22},"2026-07",{"date":257,"type":22},"2028-12",{"name":259,"class":41},"Mark Hurworth",{"id":261,"slug":262,"hasResults":12,"nctId":263,"briefTitle":264,"officialTitle":265,"acronym":4,"eligibilityCriteria":266,"healthyVolunteers":12,"sex":18,"minAge":4,"maxAge":4,"enrollmentInfo":267,"targetDuration":4,"studyType":23,"phases":269,"briefSummary":270,"conditions":271,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":272,"lastUpdatePostDateStruct":273,"startDateStruct":275,"completionDateStruct":277,"leadSponsor":279,"locationsCount":281},"100580951","motion-clinical-trial-100580951","NCT06843980","MOTION Clinical Trial","Evaluation of the MISHA® Knee System for Symptom Relief in Subjects With Medial Knee Osteoarthritis Versus the Use of Non-surgical Treatment: Randomized Clinical Trial and Comparison of Therapies for Medial Knee Osteoarthritis","Key Inclusion Criteria:\n\n1. Activity exacerbated knee pain isolated to the medial compartment and not global in nature\n2. WOMAC pain ≥ 40\n3. Failed to find relief in non-surgical treatment modalities\n\nKey Exclusion Criteria:\n\n1. Large medial osteophyte(s) or considerable extruded meniscus that may interfere with the placement or function of the device\n2. Poor bone quality (e.g., bony erosion, osteopenia, osteoporosis)\n3. Ligamentous instability\n4. Active or recent knee infection\n5. Inflammatory joint disease, including sequelae of viral infections\n6. Suspected or documented allergy or hypersensitivity to cobalt, chromium, nickel or other metals\n7. History of keloid, hypertrophic or contracture scaring\n8. Propensity for restrictive scar formation or adhesions with prior procedures",{"count":268,"type":22},100,[55],"Prospective, multicenter, two-arm, 2:1 randomized controlled trial (RCT) comparing the benefits in subjects with medial knee osteoarthritis who are treated with either the MISHA Knee System or with non-surgical treatment.\n\nThis is the first randomized head-to-head study comparing outcomes from subjects treated with the MISHA Knee System.",[28],"2026-07-13",{"date":274,"type":34},"2026-07-14",{"date":276,"type":34},"2025-02-13",{"date":278,"type":22},"2030-06-30",{"name":280,"class":41},"Moximed",9,{"id":283,"slug":284,"hasResults":12,"nctId":285,"briefTitle":286,"officialTitle":287,"acronym":288,"eligibilityCriteria":289,"healthyVolunteers":12,"sex":18,"minAge":290,"maxAge":291,"enrollmentInfo":292,"targetDuration":4,"studyType":23,"phases":294,"briefSummary":295,"conditions":296,"keywords":299,"overallStatus":112,"whyStopped":4,"lastUpdateSubmitDate":305,"lastUpdatePostDateStruct":306,"startDateStruct":308,"completionDateStruct":310,"leadSponsor":312,"locationsCount":4},"100647244","effect-of-tergase-injection-on-reducing-edema-after-bilateral-total-knee-arthroplasty-100647244","NCT07705165","Effect of Tergase Injection on Reducing Edema After Bilateral Total Knee Arthroplasty","A Randomized, Split Body, Evaluator-blinded, Trial on the Effect of Tergase Injection (Berahyaluronidase Alfa) on Reducing Edema After Both Total Knee Arthroplasty","ALT-TKA","Inclusion Criteria:\n\n1. Adult males and females aged 60 years or older and 85 years or younger.\n2. Patients scheduled for bilateral total knee arthroplasty due to degenerative knee osteoarthritis with a Kellgren-Lawrence grade of III or IV confirmed by imaging within the last 4 weeks.\n3. Patients experiencing knee joint pain of 5 or higher on a 10-point Visual Analogue Scale (VAS) during daily activities, such as walking on flat ground.\n4. Patients with the willingness and ability to follow the physician's instructions, including joint exercises.\n5. Patients classified as American Society of Anesthesiologists (ASA) Physical Status Class I or II.\n6. Patients who have received a full explanation of the clinical trial and have voluntarily provided written informed consent to participate.\n\nExclusion Criteria:\n\n1. Participants or their family members with ongoing or a history of autoimmune diseases.\n2. Patients with secondary osteoarthritis of the knee.\n3. Patients with inflammatory arthritis (such as rheumatoid arthritis, lupus arthropathy, psoriatic arthritis) or crystal-induced arthropathy.\n4. Patients with a serum protein level of 5.5 g\u002FdL or less.\n5. Patients with clinical laboratory results that are contraindications for total knee arthroplasty:\n\n   1. WBC \\\u003C3,000\u002FμL or \\>12,000\u002FμL\n   2. CRP \\>10 mg\u002FL\n   3. Hb \\\u003C10 g\u002FdL\n   4. Platelet count \\\u003C100,000\u002FμL\n   5. INR \\>1.5\n   6. eGFR \\\u003C30 mL\u002Fmin\u002F1.73 m²\n   7. AST or ALT \\>3 times the upper limit of normal\n   8. Fasting blood glucose \\>200 mg\u002FdL\n6. Patients with a history of drug abuse or dependence.\n7. Presence of local infection or sepsis in the affected lower limb, or a history of neurological abnormalities within the past 6 months.\n8. History of major joint surgery within 90 days.\n9. Patients who received systemic steroid treatment within 3 months prior to surgery.\n10. Patients who sustained a serious injury or received an injection in the target knee that may interfere with evaluation within 3 months prior to the screening visit.\n11. Patients with infections requiring hospitalization and administration of antibiotics or antimicrobics.\n12. Patients with any clinically significant medical condition that may interfere with study completion or outcome assessment, including but not limited to:\n\n    1. Congenital heart disease, clinically significant cardiovascular disease, renal dysfunction, or uncontrolled diabetes.\n    2. Neuromuscular disorders affecting the lower limbs.\n    3. Severe bleeding or coagulation disorders.\n    4. Severe knee instability that cannot be corrected with cruciate-retaining total knee arthroplasty.\n    5. Severe knee deformity, defined as flexion contracture ≥30 degrees or varus\u002Fvalgus deformity ≥30 degrees.\n    6. Opioid dependence, defined as consumption of ≥100 mg morphine-equivalent opioids per week for more than 3 months before surgery.\n    7. Inability to assess pain using the Visual Analogue Scale, including cognitive or language impairment.\n    8. Venous congestion of the lower extremity.\n    9. Morbid obesity, defined as body mass index \\>40 kg\u002Fm².\n13. History of shock or hypersensitivity to Tergase inj. or its components.\n14. Patients deemed unsuitable for this study by the investigator, such as those with psychiatric disorders.\n15. Patients currently participating in another clinical trial.","60 Years","85 Years",{"count":293,"type":22},30,[55],"This clinical trial is conducted to compare and evaluate the efficacy and safety of Tergase injection (4,500 IU) in reducing postoperative edema between treated and untreated knees in patients undergoing bilateral total knee arthroplasty (TKA).\n\nPrior to participation, all subjects receive a full explanation of the study and provide voluntary written informed consent. Only subjects who meet the inclusion and exclusion criteria through screening procedures are enrolled. Enrolled subjects are randomly assigned to the experimental and control groups in a 1:1 ratio per knee, utilizing a split-body clinical trial design that compares both knees of the same subject.\n\nThe analysis target is 60 knees obtained from a total of 30 subjects. According to the randomization results, the knee assigned to the experimental group receives a subcutaneous injection of 3 vials (4,500 IU) of Tergase, while the contralateral knee serves as the untreated control group.\n\nBy including both the experimental and control groups within the same subject, inter-individual variation is minimized. While the investigator performing the injection is aware of the assignment, the subject remains blinded.\n\nTo overcome the physical impossibility of blinding the injector due to the route of administration and drug characteristics, an 'Evaluator-Blinded' design is adopted to maintain objectivity equivalent to a double-blind study. To achieve this, the unblinded injector and the blinded evaluator who measures efficacy outcomes are strictly separated, and operational blinding is maintained by blocking information exchange between the two groups.\n\nSubjects are evaluated for efficacy and safety during hospitalization or outpatient visits at Day 1, 2, 3, 5, Week 2, Week 6, and Month 3 after bilateral TKA. Participation ends upon completion of the planned visits.",[28,297,298],"Postoperative Edema","Bilateral Total Knee Arthroplasty",[300,301,302,303,297,304],"Tergase","Berahyaluronidase alfa","Recombinant human hyaluronidase","Total Knee Arthroplasty","Split-body trial","2026-07-12",{"date":307,"type":34},"2026-07-15",{"date":309,"type":22},"2026-08-01",{"date":311,"type":22},"2028-03-31",{"name":313,"class":67},"Man Soo Kim",{"id":315,"slug":316,"hasResults":12,"nctId":317,"briefTitle":318,"officialTitle":319,"acronym":4,"eligibilityCriteria":320,"healthyVolunteers":215,"sex":18,"minAge":4,"maxAge":4,"enrollmentInfo":321,"targetDuration":4,"studyType":323,"phases":4,"briefSummary":324,"conditions":325,"keywords":327,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":333,"lastUpdatePostDateStruct":334,"startDateStruct":335,"completionDateStruct":337,"leadSponsor":339,"locationsCount":68},"100647083","serum-fetuin-a-and-comp-levels-in-knee-osteoarthritis-100647083","NCT07706569","Serum Fetuin-A and COMP Levels in Knee Osteoarthritis","The Relationship Between Clinical and Radiographic Severity of Knee Osteoarthritis and Serum Fetuin-A and COMP Levels: A Controlled Cross-Sectional Study","Inclusion Criteria:\n\n\\- Diagnosis of knee osteoarthritis according to ACR (American College of Rheumatology) criteria. Knee osteoarthritis classified as Grade 2, 3, or 4 according to Kellgren-Lawrence (K-L) grading. Volunteering to participate and providing signed informed consent.\n\nExclusion Criteria:\n\n* Secondary post-traumatic knee osteoarthritis, history of major knee injury or joint infection. Signs of acute joint inflammation (swelling, heat increase, erythema). History of knee surgery (open or arthroscopic). Systemic inflammatory or autoimmune diseases. History of malignancy. Advanced renal or hepatic disease. Diagnosis of Diabetes Mellitus. Current use of systemic corticosteroids. Symptomatic osteoarthritis in other major joints (hip, hand, ankle, spine). Active systemic infection (fever ≥ 38, cough, diarrhea, dysuria, leukocytosis, or elevated CRP).",{"count":322,"type":22},180,"OBSERVATIONAL","The purpose of this study is to investigate the relationship between the clinical and radiographic severity of knee osteoarthritis (OA) and the serum levels of specific biomarkers, namely Fetuin-A and Cartilage Oligomeric Matrix Protein (COMP). Osteoarthritis is a degenerative joint disease characterized by cartilage breakdown and low-grade inflammation. Investigating these biomarkers may help healthcare providers better understand the disease pathology, potentially leading to earlier diagnosis and improved tracking of disease progression. The study will compare two distinct groups: a patient group consisting of 120 individuals diagnosed with Grade 2-4 knee osteoarthritis, and a control group of 60 age- and sex-matched healthy volunteers with no history of joint disorders. Participants will undergo radiographic evaluations using the Kellgren-Lawrence classification system, alongside clinical and functional assessments, including pain severity scales, mobility metrics, and functional questionnaires. Fasting blood samples will be collected from all participants to measure serum Fetuin-A and COMP levels via laboratory analysis, and the Systemic Inflammation Response Index (SIRI) will be calculated. The collected data will be statistically analyzed to determine if biomarker levels significantly correlate with the severity of knee joint degeneration and functional impairment.",[326,28],"Knee Osteoarthritis",[28,328,329,330,331,332],"Fetuin-A","Cartilage Oligomeric Matrix Protein","Biological Biomarkers","Systemic Inflammation Response Index","Cross-Sectional Studies","2026-07-11",{"date":307,"type":34},{"date":336,"type":34},"2026-04-01",{"date":338,"type":22},"2026-12-30",{"name":340,"class":341},"Antalya Training and Research Hospital","OTHER_GOV",{"id":343,"slug":344,"hasResults":12,"nctId":345,"briefTitle":346,"officialTitle":347,"acronym":4,"eligibilityCriteria":348,"healthyVolunteers":12,"sex":18,"minAge":4,"maxAge":4,"enrollmentInfo":349,"targetDuration":4,"studyType":23,"phases":351,"briefSummary":352,"conditions":353,"keywords":354,"overallStatus":112,"whyStopped":4,"lastUpdateSubmitDate":360,"lastUpdatePostDateStruct":361,"startDateStruct":363,"completionDateStruct":365,"leadSponsor":367,"locationsCount":4},"100644699","standard-versus-novel-rfa-for-chronic-knee-pain-in-osteoarthritis-100644699","NCT07674082","Standard Versus Novel RFA for Chronic Knee Pain in Osteoarthritis","A Prospective Pilot Study Comparing Standard and Novel Radiofrequency Ablation Protocols for Chronic Knee Pain in Osteoarthritis","Inclusion Criteria:\n\n1. Any patient with knee osteoarthritis receiving knee RFA.\n2. Stable pain medications for past 1 month.\n3. Able to speak English.\n\nExclusion Criteria:\n\n1. Scheduled for knee surgery within 6 months following RFA procedure.\n2. Participating in another study that the Principal Investigator or Co-Investigators deem will interfere with the interpretation of the results.",{"count":350,"type":22},24,[55],"Brief Summary\n\nThe goal of this pilot study is to evaluate the feasibility and safety of conducting a randomized comparison of two standard-of-care knee radiofrequency ablation (RFA) techniques in adults with chronic knee pain related to knee osteoarthritis.\n\nParticipants who are already scheduled to receive knee RFA as part of their standard clinical care will be randomized to receive either a standard 3-target (standard) RFA protocol or a 6-target (novel) RFA protocol. The main purpose of this pilot study is to determine whether a future larger randomized trial comparing these two RFA approaches is feasible and safe to conduct.\n\nParticipants will complete questionnaires about pain, knee function, and stiffness at baseline and at follow-up timepoints for up to 12 months after the RFA procedure. Preliminary pain relief outcomes will also be explored to help inform the design of a future definitive trial.\n\nParticipants already scheduled for a knee RFA procedure as part of their standard of care for pain related to knee osteoarthritis will answer online survey questions about their pain for up to 12 months.",[28],[355,356,357,358,359],"radiofrequency ablation","radiofrequency","needle insertion","knee pain","pain management","2026-07-02",{"date":362,"type":34},"2026-07-06",{"date":364,"type":22},"2026-07-20",{"date":366,"type":22},"2029-08-20",{"name":368,"class":67},"Lawson Research Institute of St. Joseph's",{"id":370,"slug":371,"hasResults":12,"nctId":372,"briefTitle":373,"officialTitle":373,"acronym":374,"eligibilityCriteria":375,"healthyVolunteers":12,"sex":18,"minAge":77,"maxAge":290,"enrollmentInfo":376,"targetDuration":4,"studyType":23,"phases":377,"briefSummary":378,"conditions":379,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":381,"lastUpdatePostDateStruct":382,"startDateStruct":383,"completionDateStruct":385,"leadSponsor":386,"locationsCount":68},"100553798","analysis-of-the-pathophysiological-and-functional-state-of-the-knee-joint-100553798","NCT06490770","Analysis of the Pathophysiological and Functional State of the Knee Joint","Gait-MRI-Knee","Inclusion Criteria:\n\n* Knee pain and\u002For loss of functionality\n* Kellgren-Lawrence grade less than or equal to 2\n* Arthroscopic evidence of cartilage tissue lesions\n* Evidence of cartilage and\u002For meniscal tissue degeneration and\u002For subchondral bone marrow lesions\n\nExclusion Criteria:\n\n* History\u002Fevidence of previous partial or total knee prosthesis interventions\n* Inability to provide informed consent\n* Conditions or physical disorders incompatible with the use of MRI and electrical stimulation (implanted active and passive biomedical devices, epilepsy, severe venous insufficiency in the lower limbs)",{"count":7,"type":22},[55],"Osteoarthritis is the most common degenerative condition affecting the knee joint globally, with an incidence of about 7% of the population. In Italy, it affects approximately 3.9 million people, with a direct treatment cost of around €2.5 billion. At the joint level, osteoarthritis manifests with pain and reduced functionality, worsening as the disease progresses and severely limiting knee movement. Compounding this, osteoarthritis can impact both elderly and younger individuals due to traumatic factors.\n\nDespite its significant impact, effective treatments for osteoarthritis that address its underlying causes are still lacking, focusing mainly on symptom management. Therefore, improving diagnostic and prognostic approaches is crucial to better understand its onset and progression.\n\nMRI is a primary diagnostic tool for assessing the knee joint's pathophysiological state. It uses tissue-specific sequences to investigate joint homeostasis in detail, although it primarily provides insights into morphology, structure, and tissue composition rather than functional changes within the joint. This limitation is noteworthy because joint homeostasis involves complex interactions among biomechanical, structural, and biological processes, which are directly influenced by osteoarthritis.\n\nGait analysis provides valuable diagnostic information on joint function. By integrating sensor measurements and electronic systems with patient-specific musculoskeletal models derived from MRI morphometric data, it is possible to assess the forces and moments within the joint during specific movements.\n\nGiven that osteoarthritis affects the entire joint, employing multidisciplinary approaches can enhance diagnostic precision and provide insights into the progressive impact of degenerative conditions like osteoarthritis on joint health.",[28,380],"Cartilage Degeneration","2026-06-30",{"date":360,"type":34},{"date":384,"type":34},"2025-07-09",{"date":38,"type":22},{"name":387,"class":67},"Istituto Ortopedico Rizzoli",{"id":389,"slug":390,"hasResults":12,"nctId":391,"briefTitle":392,"officialTitle":393,"acronym":394,"eligibilityCriteria":395,"healthyVolunteers":12,"sex":18,"minAge":77,"maxAge":4,"enrollmentInfo":396,"targetDuration":4,"studyType":23,"phases":398,"briefSummary":399,"conditions":400,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":403,"lastUpdatePostDateStruct":404,"startDateStruct":406,"completionDateStruct":408,"leadSponsor":409,"locationsCount":410},"100515037","phase-2-a-master-protocol-study-ly900028-of-multiple-intervention-specific-appendices-isas-in-participants-with-chronic-pain-100515037","NCT05986292","A Master Protocol Study (LY900028) of Multiple Intervention-Specific-Appendices (ISAs) in Participants With Chronic Pain","A Master Protocol for Randomized, Placebo-Controlled, Phase 2 Clinical Trials of Multiple Interventions for the Treatment of Chronic Pain","CPMP","Inclusion Criteria:\n\n* have a visual analog scale (VAS) pain value \\>40 and \\\u003C95 at screening and prerandomization screening.\n* have a history of daily pain for at least 12 weeks based on participant report or medical history\n* have a value of ≤30 on the pain catastrophizing scale\n* have a body mass index \\\u003C40 kilogram\u002Fsquare meter (kg\u002Fm²) (inclusive)\n* are willing to maintain a consistent regimen of any ongoing nonpharmacologic pain-relieving therapies (for example, physical therapy) and will not start any new nonpharmacologic pain-relieving therapies during study participation.\n* are willing to discontinue all medications taken for chronic pain conditions, except rescue medication for the duration of the study\n\nExclusion Criteria:\n\n* have second- or third-degree atrioventricular (AV) heart block or AV dissociation or history of ventricular tachycardia\n* have had a procedure within the past 6 months intended to produce permanent sensory loss in the target area of interest (for example, ablation techniques)\n* have surgery planned during the study for any reason, related or not to the disease state under evaluation.\n* have, in the judgment of the investigator, an acute, serious, or unstable medical condition or a history or presence of any other medical illness that would preclude study participation.\n* have had cancer within 2 years of baseline, except for cutaneous basal cell or squamous cell carcinoma resolved by excision.\n* have fibromyalgia\n* have substance use disorder as defined by the Diagnostic and Statistical Manual of Mental Disorders (5th edition; DSM-5; American Psychiatric Association)\n* have any clinically important abnormality at screening, as determined by investigator, in physical or neurological examination, vital signs, electrocardiogram (ECG), or clinical laboratory test results that could be detrimental to the participant or could compromise the study.\n* have a positive human immunodeficiency virus (HIV) test result at screening\n* have a history of alcohol, illicit drug, analgesic or narcotic use disorder within 2 years prior to screening.",{"count":397,"type":22},10000,[25],"The purpose of the chronic pain master protocol is to compare independent pain interventions and establish an overarching structure for the disease-state addenda (DSA) and intervention-specific appendices (ISAs). The ISAs may start independently of other ISAs as interventions become available for clinical testing.",[28,401,402],"Diabetic Neuropathic Pain","Chronic Low-back Pain","2026-06-19",{"date":405,"type":34},"2026-06-23",{"date":407,"type":34},"2020-01-30",{"date":38,"type":22},{"name":40,"class":41},64,{"id":412,"slug":413,"hasResults":12,"nctId":414,"briefTitle":415,"officialTitle":416,"acronym":4,"eligibilityCriteria":417,"healthyVolunteers":12,"sex":18,"minAge":77,"maxAge":4,"enrollmentInfo":418,"targetDuration":4,"studyType":23,"phases":420,"briefSummary":421,"conditions":422,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":423,"lastUpdatePostDateStruct":424,"startDateStruct":425,"completionDateStruct":427,"leadSponsor":429,"locationsCount":68},"100532117","effects-of-movement-retraining-on-knee-loading-in-individuals-with-knee-osteoarthritis-100532117","NCT06208631","Effects of Movement Retraining on Knee Loading in Individuals With Knee Osteoarthritis","Effects of Haptic Movement Retraining on Osteoarthritis Progression","Inclusion Criteria:\n\n* Medial and\u002For lateral compartment knee osteoarthritis\n* Diagnosed with knee osteoarthritis of at least six months duration\n* Ambulatory without aids\n* Able to walk for at least 60 minutes\n* Typical pain rating of 1-4 on scale of 0-10\n* Able to reduce gastrocnemius muscle activation by 10% from baseline\n\nExclusion Criteria:\n\n* History of symptomatic arthritis in lower limb joints other than the knees\n* Replacement of any lower extremity joint\n* Symptoms originating from the patellofemoral joint\n* Body mass index equal to or greater than 35\n* Nerve or muscle disease associated with walking difficulty\n* History of rheumatoid arthritis, gout, or autoimmune disease\n* History of lower limb fracture or surgery requiring hospitalization\n* Pregnant",{"count":419,"type":22},31,[55],"This study investigates how well individuals with knee osteoarthritis can learn to alter their calf muscle activation using haptic biofeedback while walking and evaluates how these changes affect knee loading.\n\nPrior research has utilized musculoskeletal simulations to determine that reducing the activation of one of the calf muscles, the gastrocnemius, can have a large impact on reducing knee loading. However, this has not been tested in individuals with knee osteoarthritis. In this study, participants will be trained to alter the activation of their gastrocnemius muscle, by receiving haptic feedback after each step. The feedback will indicate how the participant changed their muscle activation relative to baseline. Some participants will train on a treadmill in the laboratory for up to two sessions, with 30 minutes of walking with feedback in each session. If a participant can learn to adjust their muscle activation in the first training session, they will be able to complete the second training session. Other participants will train outside the laboratory for one session with 30 minutes of walking with feedback to investigate changes in knee loading while using the new walking strategy during over-ground walking.\n\nThe movement data collected during the training sessions will be used as inputs to computer simulations of the musculoskeletal system to determine if walking with the new muscle activation strategy reduces knee loading.",[28],"2026-06-18",{"date":405,"type":34},{"date":426,"type":34},"2024-01-18",{"date":428,"type":22},"2026-12",{"name":430,"class":67},"Stanford University",{"id":432,"slug":433,"hasResults":12,"nctId":434,"briefTitle":435,"officialTitle":436,"acronym":4,"eligibilityCriteria":437,"healthyVolunteers":12,"sex":18,"minAge":77,"maxAge":4,"enrollmentInfo":438,"targetDuration":4,"studyType":23,"phases":440,"briefSummary":441,"conditions":442,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":444,"lastUpdatePostDateStruct":445,"startDateStruct":447,"completionDateStruct":449,"leadSponsor":451,"locationsCount":68},"100638529","cryotherapy-versus-standard-care-in-reducing-opioid-consumption-after-total-knee-arthroplasty-100638529","NCT07630337","Cryotherapy Versus Standard Care in Reducing Opioid Consumption After Total Knee Arthroplasty","Efficacy of Cryotherapy Versus Standard Care in Reducing Opioid Consumption After Total Knee Arthroplasty: A Randomized Controlled Trial","Inclusion Criteria:\n\n* Age between 60 and 80 years\n* Scheduled to undergo primary total knee arthroplasty for knee osteoarthritis\n* Ability to understand the study procedures and provide written informed consent\n\nExclusion Criteria:\n\n* Revision total knee arthroplasty\n* Vascular disorders affecting the lower limbs\n* Body mass index (BMI) greater than 35 kg\u002Fm²\n* Active knee infection\n* Severe preoperative limitations in knee mobility",{"count":439,"type":22},74,[55],"The goal of this clinical trial is to learn if compressive cryotherapy can reduce postoperative opioid consumption in patients undergoing primary total knee arthroplasty. It will also evaluate whether compressive cryotherapy improves postoperative recovery compared with standard care using conventional ice application. The main questions it aims to answer are:\n\nDoes compressive cryotherapy reduce the total consumption of opioids during the first 7 days after total knee arthroplasty?\n\nDoes compressive cryotherapy reduce postoperative pain and improve early recovery compared with standard cryotherapy?\n\nResearchers will compare compressive cryotherapy using the Game Ready® device with standard care using traditional ice packs to determine whether the intervention reduces opioid consumption and improves postoperative outcomes.\n\nParticipants will:\n\nBe randomly assigned to receive compressive cryotherapy or standard cryotherapy with ice packs after surgery.\n\nApply the assigned treatment four times per day during the first 7 postoperative days.\n\nRecord daily pain levels using a visual analog scale (VAS) and document opioid consumption in a pain diary.\n\nAttend a follow-up visit on postoperative day 7 for evaluation of knee swelling, hematoma size, and recovery using the QoR-15 questionnaire.",[28,443,303],"Postoperative Pain","2026-06-01",{"date":446,"type":34},"2026-06-05",{"date":448,"type":34},"2026-02-01",{"date":450,"type":22},"2027-06-01",{"name":452,"class":67},"Hospital Italiano de Buenos Aires",{"id":454,"slug":455,"hasResults":12,"nctId":456,"briefTitle":457,"officialTitle":458,"acronym":4,"eligibilityCriteria":459,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":460,"targetDuration":4,"studyType":23,"phases":462,"briefSummary":464,"conditions":465,"keywords":466,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":469,"lastUpdatePostDateStruct":470,"startDateStruct":472,"completionDateStruct":474,"leadSponsor":476,"locationsCount":68},"100552830","phase-4-knee-osteoarthritis-treatment-with-zilretta-vs-kenalog-in-the-context-of-type-ii-diabetes-100552830","NCT06478186","Knee Osteoarthritis Treatment With Zilretta vs. Kenalog in the Context of Type II Diabetes","RCT to Evaluate the Effects of Zilretta (Triamcinolone Acetonide- Extended Release) and Kenalog (Triamcinolone Acetonide- Immediate Release) on Blood Glucose in Subjects With Osteoarthritis of the Knee and Type 2 Diabetes Mellitus","Inclusion Criteria:\n\n* 1\\. Written consent to participate in the study. 2. Willingness and ability to comply with the study procedures and visit schedules and ability to follow verbal and written instructions.\n\n  3\\. Male or female ≥40 years of age. 4. Females with negative pregnancy test, who are not breastfeeding and have no intention to become pregnant during the time from screening through EOS.\n\n  5\\. Type 2 DM for at least 1 year prior to Screening. 6. Currently being treated with injectable (except insulin) and\u002For oral antidiabetic agents with stable doses for at least 1 month prior to Screening.\n\n  7\\. HbA1c 6.5-9% (in past 8 weeks). 8. Estimated glomerular filtration rate (eGFR) ≥50 mL\u002Fmin\u002F1.73 m2. (in past 8 weeks) 9. Triglycerides \\\u003C500 mg\u002FdL (in past 8 weeks) 10. Painful symptoms associated with OA of the knee for ≥6 months prior to Screening (NRS of 4-9 during most of the 30 days prior to enrollment).\n\n  11\\. Currently meets modified ACR criteria (clinical and radiological) for OA (Altman et al, 1986) as follows:\n  1. Knee pain\n  2. At least 1 of the following:\n\n     * Stiffness \\\u003C30 minutes\n     * Crepitus\n  3. Osteophytes 12. Index knee pain more than 15 days over the last month (as reported by the subject).\n\n     13\\. Kellgren-Lawrence Grade 2-4. 14. Willingness to wear a CGM device uninterrupted for 24 hours per day throughout the required time during the study and comply to the correct use requirements of CGM throughout the trial and perform self BG checks as directed.\n\n     15\\. Adequate BG data collected during the pretreatment phase (Day -10 through Day -1) ≥70% data available.\n\n     Exclusion Criteria:\n\n     Disease-related Criteria\n     1. Reactive arthritis, rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, or arthritis associated with inflammatory bowel disease.\n     2. History of infection in the index knee joint.\n     3. Clinical signs and symptoms of active knee infection or crystal disease of the index knee within 1 month of Screening.\n     4. Presence of surgical hardware or other foreign body in the index knee.\n     5. Unstable joint (such as a torn anterior cruciate ligament) within 12 months of Screening.\n     6. Moderate or severe kidney, liver, or thyroid disease.\n     7. Glaucoma.\n     8. Active cancer. Previous or Concomitant Treatment-related Criteria\n     9. IA corticosteroid (investigational or marketed) in any joint within 3 months of Screening.\n     10. IA hyaluronic acid (investigational or marketed) in the index knee within 6 months of Screening.\n     11. IV or intramuscular (IM) corticosteroids (investigational or marketed) within 3 months of Screening.\n     12. Oral corticosteroids (investigational or marketed) within 1 month of Screening.\n     13. Inhaled, intranasal, or topical corticosteroids (investigational or marketed) within 2 weeks of Screening.\n     14. Any other IA investigational device, drug\u002Fbiologic within 6 months of Screening or 5 half-lives (whichever is longer).\n     15. Prior arthroscopic or open surgery of the index knee within 12 months of Screening.\n     16. Planned\u002Fanticipated surgery of the index knee or any other surgery during the study period.\n     17. Use of acetaminophen, or acetaminophen-containing products, from Screening through Day 14 (completion of post-treatment BG monitoring).\n     18. Subjects on Coumadins with INR ≥5 will be excluded (Bashir et al, 2015) Subject-related Criteria\n     19. Known hypersensitivity to any form of triamcinolone.\n     20. History of sarcoidosis or amyloidosis.\n     21. Active or history of malignancy within the last 3 years, except for resected basal cell carcinoma, squamous cell carcinoma of the skin, or effectively managed cervical carcinoma.\n     22. Known active or quiescent systemic fungal, bacterial (including tuberculosis), viral, or parasitic infections or ocular herpes simplex.\n     23. Any infection requiring IV antibiotics within 4 weeks of Screening or infection requiring oral antibiotics within 2 weeks of Screening.\n     24. History of osteomyelitis.\n     25. Known or clinically suspected infection with human immunodeficiency virus (HIV) or hepatitis B or C viruses.\n     26. Requiring or likely to require treatment with corticosteroids during the study period based on subject medical history.\n     27. History or active Cushing's or Addison's syndrome.\n     28. Active substance abuse (drugs or alcohol), history of chronic substance abuse within the last year, or prior chronic substance abuse judged by the Investigator likely to recur during the study.\n     29. Skin breakdown at the knee where the injection would take place.\n     30. Use of immunomodulators, immunosuppressives, or chemotherapeutic agents within 2 years of Screening.\n     31. Receipt of a live or live attenuated vaccine within 3 months of Screening.\n     32. Any other clinically significant psychiatric acute or chronic medical conditions that, in the judgment of the Investigator, would preclude the use of an IA corticosteroid or NSAIDs or that could compromise subject safety, limit the subject's ability to complete or adhere to the study, and\u002For compromise the objectives of the study.",{"count":461,"type":22},120,[463],"PHASE4","A Phase 2 Randomized Study to Evaluate the Effects of triamcinolone acetonide extended-release (TA-ER; Zilretta) vs. triamcinolone acetonide immediate-release (TA-IR; Kenalog) on Blood Glucose Levels in Diabetic Subjects with Knee Osteoarthritis. Subjects should have Type 2 Diabetes Mellitus (T2DM) with HbA1C ≤9 that is managed without insulin and have been diagnosed with symptomatic unilateral or bilateral osteoarthritis (OA) of the knee, based on clinical and radiological criteria (if bilateral, then a target knee will be selected).Total study duration for individual subject will be about 4 months, which includes 3 weeks of Screening period, 10 days of pretreatment phase, treatment day, and 12 weeks of post-treatment period.",[28,135],[467,468],"Zilretta","Kenalog","2026-05-27",{"date":471,"type":34},"2026-05-28",{"date":473,"type":34},"2024-08-16",{"date":475,"type":22},"2027-01-16",{"name":477,"class":67},"University of Kansas Medical Center",{"id":479,"slug":480,"hasResults":12,"nctId":481,"briefTitle":482,"officialTitle":482,"acronym":4,"eligibilityCriteria":483,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":484,"enrollmentInfo":485,"targetDuration":4,"studyType":23,"phases":487,"briefSummary":488,"conditions":489,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":490,"lastUpdatePostDateStruct":491,"startDateStruct":493,"completionDateStruct":495,"leadSponsor":497,"locationsCount":68},"100573265","effects-of-including-interferential-current-in-a-therapeutic-exercise-program-in-individuals-with-knee-osteoarthritis-100573265","NCT06744036","Effects of Including Interferential Current in a Therapeutic Exercise Program in Individuals With Knee Osteoarthritis","Inclusion Criteria:\n\n* both sexes\n* between 40 years old and 75 years old\n* with a clinical diagnosis of unilateral KOA\n* Who has had knee pain for more than 3 months\n* With a minimum score of 3 points on the numerical pain scale\n* Morning stiffness for less than 30 minutes\n* Crepitus\n* Bone tenderness and absence of palpable heat\n\nExclusion Criteria:\n\n* Hip OA\n* Severe osteoporosis\n* Fibromyalgia\n* Clinical history of tumors or cancer\n* Active inflammatory joint diseases (rheumatoid arthritis, gout)\n* Undergoing any joint replacement in the lower extremity\n* Neurological diseases (Parkinson's disease, stroke\n* Multiple sclerosis\n* muscular dystrophies\n* Diseases involving motor neurons\n* Alzheimer's disease\n* Infected wounds or osteomyelitis in the knee region\n* Deep vein thrombosis or thrombophlebitis\n* Sensory alteration in the lower limbs\n* Cognitive and cardiopulmonary impairment that may prevent or limit the execution of exercises\n* Use of a walking assistance device\n* History of recent knee trauma\n* Having undergone any form of treatment involving physical therapy\n* intra-articular corticosteroids\n* anti-inflammatory drugs\n* opioid medication or chondroprotective in the six months before the start of the interventions","75 Years",{"count":486,"type":22},138,[55],"The first-line treatment for knee osteoarthritis (KOA) in terms of pain and functionality is physical exercise. The use of interferential current (IC) associated with other resources may be beneficial in reducing pain intensity and improving functionality. However, the effects of its simultaneous use with therapeutic exercise have not yet been fully established. The aim of this project will be to evaluate the effects of including IC in a therapeutic exercise program in relation to pain intensity, functionality, self-efficacy, maximum voluntary contraction and overall perceived effect in individuals with KOA. Therefore, research participants of both sexes, between 40 and 75 years old, with a clinical diagnosis of unilateral KOA, who have knee pain for more than 3 months, with a minimum score of 3 points on the numerical pain scale, morning stiffness for less than 30 minutes, crepitation, bone sensitivity, and absence of palpable heat will be recruited. The research participants will be randomized into three groups: therapeutic exercises (n=46) and therapeutic exercises + IC (n=46) and therapeutic exercises + IC placebo (n=46). Eight consecutive weeks of treatment will be carried out. The research participants will be evaluated before the intervention, after the end of the intervention of eight consecutive weeks of intervention and after four weeks at the end of the last week of intervention, through the instruments: numeric pain scale (NPS), Knee Injury and Osteoarthritis Outcome Score (KOOS), patient-specific functional scale (EFEP), Pain self-efficacy questionnaire (PSEQ), maximum voluntary isometric contraction (MVIC), 30-second sit-to-stand test (TSL30s), global perception scale (EPG). For data analysis, a normality test will be used to verify the distribution of the data and a statistical test appropriate for the appropriate intra and inter-group comparisons, thus considering two factors in the comparisons, time and group. A significance level of 5% will be adopted.",[28],"2026-05-21",{"date":492,"type":34},"2026-05-22",{"date":494,"type":34},"2025-01-20",{"date":496,"type":22},"2026-07-28",{"name":498,"class":67},"University of Nove de Julho",{"id":500,"slug":501,"hasResults":12,"nctId":502,"briefTitle":503,"officialTitle":504,"acronym":4,"eligibilityCriteria":505,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":101,"enrollmentInfo":506,"targetDuration":4,"studyType":23,"phases":508,"briefSummary":509,"conditions":510,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":490,"lastUpdatePostDateStruct":511,"startDateStruct":512,"completionDateStruct":514,"leadSponsor":516,"locationsCount":68},"100530458","effects-of-including-a-chronic-pain-neuroscience-education-program-for-individuals-with-knee-oa-100530458","NCT06187038","Effects of Including a Chronic Pain Neuroscience Education Program for Individuals With Knee OA","Effects of Including a Chronic Pain Neuroscience Education Program for Individuals With Knee OA: Randomized, Blinded Clinical Trial","Inclusion Criteria:\n\n* A clinical diagnosis of knee osteoarthritis (knee pain for \\> 3 months\n* Morning stiffness \\\u003C30 minutes\n* Crepitus\n* Bone tenderness, and absence of palpable heat and\u002For diagnosis established radiographically (determined by Kellgren and Lawrence grade 1 to 3 on a scale 1 up to 4)\n\nExclusion Criteria:\n\n* Hip OA\n* severe osteoporosis\n* Fibromyalgia\n* Medical history of tumors or cancer\n* Active inflammatory joint diseases (rheumatoid arthritis, gout)\n* Undergoing any lower extremity joint replacement\n* Neurological diseases (Parkinson's disease, stroke, Multiple Sclerosis, muscular dystrophy, motor neuron disease, Alzheimer's disease, cognitive and cardiopulmonary impairment that may prevent or limit the performance of exercises, use of a gait assistance device, history of recent knee trauma.\n* Having undergone any form of treatment involving physiotherapy, intra-articular corticosteroids, anti-inflammatories or chondroprotective in the last six months",{"count":507,"type":22},92,[55],"Research participants diagnosed with knee osteoarthritis will be randomized through a draw using sealed opaque envelopes indicating two groups: 1. therapeutic exercises, 2. therapeutic exercises + chronic pain neuroscience education program. The primary outcome will be functional performance using a patient-reported measure, the Knee Injury and Osteoarthritis Outcome Score (KOOS).\n\nThe selected secondary outcomes will be pain intensity by the numerical pain scale (END), physical function reported by the patient by the patient-specific functional scale (EFEP), Pain self-efficacy questionnaire (PSEQ), functional mobility by the timed up and test (TUG), general effect perceived through the global perception scale (EPG), muscle strength through Maximum Voluntary Isometric Contraction (MVIC) and functionality and disability through the World Health Organization Disability Assessment Schedule (WHODAS).",[28],{"date":492,"type":34},{"date":513,"type":34},"2024-05-28",{"date":515,"type":22},"2026-12-15",{"name":498,"class":67},{"id":518,"slug":519,"hasResults":12,"nctId":520,"briefTitle":521,"officialTitle":522,"acronym":523,"eligibilityCriteria":524,"healthyVolunteers":215,"sex":18,"minAge":77,"maxAge":525,"enrollmentInfo":526,"targetDuration":4,"studyType":23,"phases":527,"briefSummary":528,"conditions":529,"keywords":531,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":534,"lastUpdatePostDateStruct":535,"startDateStruct":536,"completionDateStruct":538,"leadSponsor":540,"locationsCount":68},"100352525","total-knee-arthroplasty-fast-track-protocol-is-the-future-100352525","NCT03869996","Total Knee Arthroplasty: Fast Track Protocol is the Future?","Randomised Controlled Study Comparing Fast Track and Standard Care Protocol on the Functional Outcomes and Hospital Stay of Total Knee Arthroplasty","FastTrack-G","Inclusion Criteria:\n\n* patients affected by knee osteoarthritis, eligible for primary total knee arthroplasty\n* BMI \\\u003C 32\n* Time up ang go test \\\u003C\u002F= 12 seconds\n* American Society of Anesthesiologists physical status classification system (ASA) \\\u003C\u002F= 2\n* preoperative hemoglobin (HB) \\>13 g\u002Fdl\n* patients eligible for spinal anesthesia\n* presence of a care-giver\n\nExclusion Criteria:\n\n* psychiatric diseases\n* preoperative use of crutches\n* ASA \\> 3\n* preoperative HB \\\u003C 13 g\u002Fdl","78 Years",{"count":410,"type":22},[55],"Fast-track total knee arthroplasty (TKA) is a well-established concept including optimized logistics and evidence-based treatment, focusing on minimizing surgical stress and improved post-operative recovery. The aim of this protocol is to compare the standard care and fast track total knee arthroplasties in terms of functional and subjective outcomes, hospital staying, number of transfusions and analgesic consumption.",[28,530],"Arthropathy of Knee",[532,533],"fast track care","total knee arthroplasty","2026-05-20",{"date":492,"type":34},{"date":537,"type":34},"2019-02-25",{"date":539,"type":22},"2026-11-01",{"name":387,"class":67},{"id":542,"slug":543,"hasResults":12,"nctId":544,"briefTitle":545,"officialTitle":546,"acronym":547,"eligibilityCriteria":548,"healthyVolunteers":12,"sex":18,"minAge":77,"maxAge":549,"enrollmentInfo":550,"targetDuration":4,"studyType":23,"phases":552,"briefSummary":553,"conditions":554,"keywords":555,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":559,"lastUpdatePostDateStruct":560,"startDateStruct":561,"completionDateStruct":563,"leadSponsor":565,"locationsCount":567},"100565566","is-non-surgical-care-using-treat-to-target-multimodal-medical-strategies-able-to-delay-or-avoid-total-knee-replacement-100565566","NCT06643845","Is Non Surgical CaRE Using Treat to Target Multimodal meDIcal Strategies aBLE to Delay or Avoid Total Knee Replacement?","Is Non Surgical CaRE Using Treat to Target Multimodal meDIcal Strategies aBLE to Delay or Avoid Total Knee Replacement? (INCREDIBLE)","INCREDIBLE","Inclusion Criteria:\n\n* Age 18-90 years old\n* Femoro-tibial osteoarthritis Kellgren stage stage≥ 2 without laxity in extension;\n* A proposal of total knee replacement by a surgeon;\n* No corticosteroid joint injection within 3 months;\n* Visual analogic score pain (VAS) \\>40\u002F100 but \\\u003C90\u002F100 or Western Ontario and McMaster Universities (WOMAC) Osteoarthritis Index function sub scale \\>40\u002F100 at inclusion;\n* Wish to discuss medical care;\n* Able to consent and having signed a consent form.\n\nExclusion Criteria:\n\n* Contraindication or no indication to surgery or medical care (severe infection for example)\n* Inflammatory arthritis\n* Lack of social insurance\n* Symptomatic (VAS pain \\>40) contralateral knee or hip osteoarthritis (with or without replacement)\n* Pregnant or breastfeeding woman\n* Patient under court protection, guardianship, curatorship\n* Patient deprived of liberty","90 Years",{"count":551,"type":22},1000,[55],"Knee is the most common site of osteoarthritis. Treatment of knee osteoarthritis starts with a full course of medical therapy, followed by surgery to replace the knee with a prosthesis if this strategy fails, or in advanced cases. However, the new recommendations of the French rheumatology society, which evaluate the various treatments and position them in the treatment plan, are not well known, and the definition of a complete treatment remains unclear. The vast majority of patients are therefore referred to a surgeon after having tried a small part of the therapeutic arsenal (generally analgesics and corticosteroid or hyaluronic acid infiltrations). The goal of this study is to to select patients most likely to gain from surgery and to develop strategies that avoid the need for major surgery.",[28],[556,557,558],"Surgery","Arthroplasty","Total knee replacement","2026-05-19",{"date":492,"type":34},{"date":562,"type":34},"2025-10-17",{"date":564,"type":22},"2031-04",{"name":566,"class":67},"University Hospital, Brest",21,{"id":569,"slug":570,"hasResults":12,"nctId":571,"briefTitle":572,"officialTitle":573,"acronym":4,"eligibilityCriteria":574,"healthyVolunteers":12,"sex":18,"minAge":77,"maxAge":4,"enrollmentInfo":575,"targetDuration":4,"studyType":23,"phases":577,"briefSummary":578,"conditions":579,"keywords":580,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":583,"lastUpdatePostDateStruct":584,"startDateStruct":586,"completionDateStruct":588,"leadSponsor":590,"locationsCount":592},"100586594","phase-3-a-study-to-investigate-the-treatment-effect-of-subcutaneous-injections-of-pentosan-polysulfate-sodium-compared-with-placebo-in-adult-participants-with-knee-osteoarthritis-pain-100586594","NCT06917404","A Study to Investigate the Treatment Effect of Subcutaneous Injections of Pentosan Polysulfate Sodium Compared With Placebo in Adult Participants With Knee Osteoarthritis Pain.","A Phase 3, Randomised, Double-Blind, Placebo-Controlled Multi-Centre Study to Evaluate the Treatment Effect of Pentosan Polysulfate Sodium Compared to Placebo in Participants With Knee Osteoarthritis Pain","Inclusion Criteria:\n\n1. Participant must be ≥18 years of age inclusive, at the time of signing the informed consent.\n2. Clinical diagnosis of OA in the index knee by American College of Rheumatology 1986 criteria.\n3. Radiographic diagnosis (confirmed by radiologist) of knee OA classified K-L grade 2, 3, or 4 on standing anterior-posterior X-ray of the index knee.\n4. Participant is unresponsive for at least 6 months preceding Screening to any two combinations of OA therapies (one from each A and B) within the last 12 months that include: A.) conservative non-pharmacologic therapy (exercise, weight loss, physical therapy) or simple analgesics (e.g., acetaminophen) and B.) pharmacological treatment (topical or oral NSAIDs \\[or cyclooxygenase (COX) inhibitor\\], or intra-articular \\[IA\\] injections), or participant is unable to take NSAIDs because of contraindication or inability to tolerate.\n5. Average daily pain (ADP) numerical rating scale (NRS) score of 4-9 in the index knee at Screening.\n6. Baseline average weekly ADP NRS score of 4-9 in the index knee in the 7 days prior to randomization.\n7. No more than one 24-hr average pain score (0-10 NRS) reported as \"10\" during the 7 days prior to Day 1.\n8. Body mass index of ≥18.0 to ≤39.0 kg\u002Fm2.\n9. Female subjects of childbearing potential and Male subjects must agree to comply with protocol specified contraceptive requirements\n10. Capable of giving signed informed consent, which includes compliance with the requirements and restrictions listed in the informed consent form (ICF) and in this protocol.\n11. Completion of at least 11 out of 14 ADP NRS scores for at least 14 days prior to randomisation.\n12. Current non-pharmacologic treatment regimen for knee OA (excluding knee brace) must be stable for at least 2 weeks before Day 1 and remain stable throughout the study. Participant must be willing to abstain from starting a new or changing their non-pharmacologic treatment regimen for the duration of the study.\n13. Willing to stop treatment with oral and topical NSAIDs, and all other systemic pain medications (except allowed rescue medication) from 2 weeks before Day 1 to end of study.\n14. Agrees to use acetaminophen\u002Fparacetamol or topical analgesics (topical NSAIDs are prohibited) as rescue therapy if required.\n\nExclusion Criteria:\n\n1. History of idiopathic or immune-mediated thrombocytopenia including history of HIT with or without thrombosis.\n2. History of major bleeding disorders including haemophilia.\n3. Currently active or recent history (within preceding 12 months) of a gastric or duodenal ulcer, or suspicion of gastrointestinal tract bleeding.\n4. Recent cerebral bleeding or operation on brain, spine, or eyes within 12 months of Day 1.\n5. Spinal anaesthesia within 14 days of Day 1.\n6. Fibromyalgia, regional pain caused by lumbar or cervical compression with radiculopathy, or other moderate to severe pain disorder that may confound assessments or self-evaluation of the pain associated with osteoarthritis. Participants with a present (current) history of sciatica are not eligible for participation. Participants with a history of sciatica who have been asymptomatic for ≥3 months and who have no evidence of radiculopathy or sciatic neuropathy on thorough neurologic examination are eligible for participation.\n7. History of other disease that may involve the index knee, including inflammatory joint disease such as rheumatoid arthritis (RA), seronegative spondyloarthropathy (e.g., ankylosing spondylitis, psoriatic arthritis, inflammatory bowel disease-related arthropathy), crystalline disease (e.g., gout), endocrinopathies, metabolic joint diseases, lupus erythematosus, joint infections, Paget's disease, or tumours.\n8. History of hypersensitivity to PPS, heparin or heparin-like drugs, or drugs of a similar chemical or pharmacological class.\n9. Predisposition to hypersensitivity due to multiple (2 or more) atopic diseases (such as atopic eczema, asthma, and chronic allergic rhinitis and\u002For rhinoconjunctivitis) or multiple (2 or more) severe allergies.\n10. Allergy or contraindication to tetracosactide (Synacthen®), cosyntropin (Cortrosyn®).\n11. Allergy or contraindication to gadolinium.\n12. Chronic medical conditions including but not limited to those stated below requiring medical regime changes within 60 days before Day 1.\n\n    Concurrent unstable peripheral, cardiac, and cerebral vascular disease, poorly controlled chronic obstructive pulmonary disease and asthma, coagulopathies, uncontrolled neurological conditions, active tuberculosis, active infections, symptomatic cardiac arrhythmias, adrenal insufficiency (primary or central), nephrotic syndrome, cirrhosis (Child-Pugh stage B or C), Gilbert syndrome, uncontrolled diabetes, and uncontrolled hypothyroidism or hyperthyroidism, or mental or emotional disorders that preclude reliable study participation.\n13. History of pituitary irradiation or recent (within 1 year) history of transsphenoidal surgery.\n14. Any cancer within the previous 5 years, except for basal cell carcinomas.\n15. History or current autoimmune polyglandular syndromes.\n16. Presence of any underlying physical or psychological medical condition that, in the opinion of the Investigator, would make it unlikely that the participant will comply with the protocol or complete the study per the protocol.\n17. Current treatment with anticoagulants or antiplatelet drugs within 2 weeks before Day 1, excluding aspirin ≤150 mg\u002Fday.\n18. Previous treatment with PPS in any form.\n19. Current or recent (within 90 days before Day 1) immunosuppressive or immunomodulatory (with immunosuppressive effects) systemic therapy including but not limited to oral, inhaled, intranasal, intra-articular (IA) and topical corticosteroids (occasional use of topical, inhaled or intranasal corticosteroids is acceptable).\n20. Use of NSAIDs with 2 weeks before Day 1.\n21. Use of opioids within 6 weeks before Day 1.\n22. Use of glucosamine or chondroitin within 6 weeks before Day 1.\n23. Use of bisphosphonates and denosumab within 12 weeks before Day 1.\n24. Use of iloprost within 12 weeks before Day 1.\n25. Use of a knee brace on the index knee within 2 weeks before Day 1.\n26. Systemic steroids administered intravenously, intramuscularly, or orally for OA or other indications within 8 weeks before Day 1.\n27. Intra-articular (IA) injections to the index knee: steroids within 12 weeks before Day 1; hyaluronic acid (HA) or any other IA injections within 24 weeks before Day 1.\n28. Stem cells or platelet-rich plasma within 12 months of Day 1.\n29. Cannabinoids within 30 days before Day 1.\n30. Use of individual vitamins and dietary supplements known to alter haemostasis within 2 weeks before Day 1, including ajoene, birch bark, cayenne, Chinese black tree fungus, cumin, evening primrose oil, feverfew, garlic, ginger, ginkgo biloba, ginseng, grapeseed extract, milk thistle, omega 3 fatty acids, onion extract, St. John's wort, turmeric, vitamins C and E, vitamin K, (multivitamins allowed).\n31. Known exposure to heparin within the last 100 days as determined by history of drug use or history of the following medical conditions or interventions: cardiac bypass surgery or thromboembolic disease.\n32. Treatment with dehydroepiandrosterone sulfates (DHEA-S) within 6 weeks before Day 1.\n33. Chronic use of oral glucocorticoid receptor antagonists or cortisol synthesis inhibitors within 12 weeks before Day 1.\n34. Biotin within 72 hours before Screening.\n35. Megestrol acetate within 6 weeks before Day 1.\n36. Participation in another clinical trial or administration of any IP or experimental product within 24 weeks or 5 half-lives (whichever is longer) before Day 1.\n37. Activated partial thromboplastin time \\[aPTT\\]) \\> 36 seconds, platelets \\\u003C150,000\u002FμL, or liver enzyme tests (aspartate aminotransferase \\[AST\\] or alanine aminotransferase \\[ALT\\]) ≥ 2 × ULN at Screening.\n38. Total bilirubin ≥1.5 ULN.\n39. Active or chronic hepatitis B virus, hepatitis C virus, or uncontrolled HIV infection (detectable virus or diagnosis of AIDS); participants with HIV infection must be on chronic suppressive antiviral medication.\n40. Evidence of any of the following conditions in any screening imaging: excessive malalignment (≥10 degrees varus or valgus) of the knee, subchondral insufficiency fracture (SIF), osteonecrosis\u002Fbone infarct, osteochondritis dissecans, stress or acute fracture, atrophic OA, pathologic fracture, primary or metastatic tumour, infectious arthritis or osteomyelitis, chronic or acute, Charcot's knee joint, synovial chondromatosis, certain posterior root tears of the meniscus, bone contusion, bone marrow oedema syndrome, bone marrow infiltration, gout, severe chondrocalcinosis, other arthropathies (e.g., RA, psoriatic arthritis), systemic metabolic bone disease (e.g., Paget's disease, metastatic calcifications) or other conditions identified by a radiologist or Medical Monitor which may interfere with a participant's assessment of pain.\n41. Any clinically significant abnormalities on clinical chemistry, haematology, urinalysis, physical examination, medical history, or vital signs as judged by the Investigator (at Screening).\n42. Resting, supine blood pressure (BP) ≥160 mmHg in systolic pressure or ≥100 mmHg in diastolic pressure at Screening. If a participant is found to have uncontrolled and\u002For untreated significant hypertension at Screening and antihypertensive treatment is initiated, assessment for study eligibility should be deferred until BP and antihypertensive medication have been stable for at least 1 month. For participants with previously diagnosed hypertension, antihypertensive medications must be stable for at least 1 month before Screening.\n43. Any macular findings on clinical examination or imaging suggestive of: moderate or advanced dry macular degeneration, geographic atrophy, moderate or advanced myopic degeneration, wet macular degeneration, pattern dystrophy or other pigmentary maculopathy, moderate or severe diabetic or hypertensive retinopathy, recent retinal vascular occlusion, macular hole or advanced epiretinal membrane with associated macular oedema, retinal dystrophy, toxic retinal maculopathy, chronic central serous retinopathy, presence of significant subretinal or intraretinal fluid (OCT finding), presence of vitelliform or vitelliform-like macular changes (OCT and clinical finding), severe maculopathy not otherwise specified.\n44. Morning cortisol \\\u003C3 μg\u002FdL.\n45. Adrenocorticotropic hormone (ACTH) \\\u003C10 pg\u002FmL.\n46. US\u002FCanada only: Morning cortisol ≥3 μg\u002FdL and \\\u003C10 μg\u002FdL and peak cortisol (by ACTH stimulation \\[250 μg, IM\\] test) \\\u003C18 μg\u002FdL at both 30 min and 60 min post stimulation.\n47. Current hyperkalaemia and\u002For hyponatremia.\n48. Contraindication to MRI.\n49. Largely or wholly incapacitated (e.g., bedridden or confined to a wheelchair, permitting little or no self-care).\n50. Major surgery or anticipated surgery during the study.\n51. Currently hospitalised or any planned hospitalizations during the study.\n52. Plan for total knee reconstruction in affected knee(s) during the study.\n53. Knee surgery or trauma to the index knee within 1 year before Day 1.\n54. A history of drug or alcohol abuse and\u002For dependence within the 12 months before Screening that, in the opinion of the Investigator, may affect participant ability to comply with study requirements.\n55. An employee of the Sponsor, clinical research organisation(s), or research site personnel directly affiliated with this study or their immediate family members defined as a spouse, parent, sibling, or child, whether biological or legally adopted.",{"count":576,"type":22},466,[81],"The purpose of this study is to measure the change in pain and function with subcutaneous injections of pentosan polysulfate sodium (PPS) compared with subcutaneous injections of placebo in participants with knee OA pain.\n\nStudy details include:\n\n* The study duration will be up to 64 weeks.\n* The treatment duration will be 6 weeks.\n* The visit frequency will be twice weekly during treatment.\n* The visit\u002Fcontact frequency will be every 4-6 weeks during the 52-week Follow-up period.\n* Approximately 466 participants will be enrolled into this study.",[28],[581,582],"osteoarthritis","knee","2026-05-06",{"date":585,"type":34},"2026-05-08",{"date":587,"type":34},"2025-05-29",{"date":589,"type":22},"2027-07",{"name":591,"class":41},"Paradigm Biopharmaceuticals Ltd.",56,{"id":594,"slug":595,"hasResults":12,"nctId":596,"briefTitle":597,"officialTitle":598,"acronym":4,"eligibilityCriteria":599,"healthyVolunteers":12,"sex":18,"minAge":600,"maxAge":4,"enrollmentInfo":601,"targetDuration":4,"studyType":323,"phases":4,"briefSummary":603,"conditions":604,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":605,"lastUpdatePostDateStruct":606,"startDateStruct":608,"completionDateStruct":609,"leadSponsor":610,"locationsCount":68},"100637989","mobile-technology-to-measure-knee-health-in-osteoarthritis-100637989","NCT07580222","Mobile Technology to Measure Knee Health in Osteoarthritis","Using Mobile Technology to Extract Mechanical Markers of Joint Health and Function in Early Knee Osteoarthritis","Inclusion Criteria:\n\n* Veteran and non-Veterans\n* males and females\n* diagnosed with early knee osteoarthritis\n* qualified for and participated in the Precision Assessment of Platelet Rich Plasma for Joint Preservation study (ClinicalTrials.gov ID: NCT03460236)\n* able and willing to provide informed consent for follow-up study\n\nExclusion Criteria:\n\n* symptomatic OA in joints other than the knee in the lower body\n* joint replacement\n* rheumatic disease\n* BMI \\> 35 kg\u002Fm\\^2\n* severe systematic disease defined as American Society of Anesthesiologists (ASA) 3 or above\n* pregnant or intending to become pregnant during the study","30 Years",{"count":602,"type":22},47,"Veterans face a high prevalence of knee osteoarthritis (OA), but current diagnostic methods often miss early stages when interventions are more effective. This project will evaluate smartphone-based motion capture via OpenCap to measure joint mechanics in knee OA patients during functional activities, comparing its performance to a conventional motion capture system, patient-reported symptoms, and knee joint structure. The findings will have the potential to enable clinicians to trial OpenCap in its current form, provide insights into tracking joint health, and guide refinements to advance toward earlier diagnosis of knee OA by complementing symptom assessments with measures of joint mechanics.",[28],"2026-05-05",{"date":607,"type":34},"2026-05-12",{"date":336,"type":34},{"date":311,"type":22},{"name":206,"class":207},{"id":612,"slug":613,"hasResults":12,"nctId":614,"briefTitle":615,"officialTitle":616,"acronym":617,"eligibilityCriteria":618,"healthyVolunteers":12,"sex":18,"minAge":77,"maxAge":51,"enrollmentInfo":619,"targetDuration":4,"studyType":23,"phases":620,"briefSummary":621,"conditions":622,"keywords":627,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":632,"lastUpdatePostDateStruct":633,"startDateStruct":634,"completionDateStruct":636,"leadSponsor":638,"locationsCount":68},"100527265","promoting-sleep-to-alleviate-pain---arthroplasty-100527265","NCT06145516","Promoting Sleep to Alleviate Pain - Arthroplasty","Preoperative Sleep-promotion to Achieve Improved Postoperative Pain Control and Recovery: a Randomized, Controlled Trial","PROSAP-A","Inclusion Criteria:\n\n* age ≥18 years\n* insomnia severity index score \\>10\n* fulfill DSM-V criteria for persistent insomnia disorder\n* average pain numerical rating scale (NRS) score ≥4 (scale 0 - 10) and\u002For movement-related pain NRS score ≥4 after 5 minutes walking\n* scheduled to undergo primary (first-time, i.e., not revision surgery) TKA or THA due to osteoarthritis\n\nExclusion Criteria:\n\n* uncontrolled medical disorders\n* nightshift work\n* ongoing major depressive disorder, bipolar disorder, psychotic disorder, substance dependence\n* current history or high likelihood of primary sleep disorders (other than insomnia), including obstructive sleep apnea syndrome, narcolepsy, nocturnal myoclonus\n* severely impaired vision (precluding ability to take part of study interventions)",{"count":268,"type":22},[55],"PROSAP-A is a perioperative randomized, controlled trial with a 12-month follow-up period after total knee arthroplasty (TKA) or total hip arthroplasty (THA), aiming to investigate both acute and long-term postoperative effects of preoperative sleep-promotion. Participants with clinically significant insomnia symptoms will be randomized to a brief, hybrid version of cognitive behavioral therapy for insomnia (CBT-I) or sleep education therapy, administered over a 4-week period, prior to surgery. The primary objective is to evaluate effects of preoperative sleep-promotion on acute postoperative pain control. Secondary objectives include evaluation of postoperative sleep, recovery, mental health, cognitive function and alterations in blood biomarkers.",[28,623,624,556,625,626],"Osteoarthritis, Hip","Insomnia","Pain, Postoperative","Postoperative Complications",[581,533,628,629,630,631],"total hip arthroplasty","insomnia","sleep disturbance","postoperative pain","2026-04-29",{"date":583,"type":34},{"date":635,"type":34},"2025-09-01",{"date":637,"type":22},"2030-12-01",{"name":639,"class":67},"Uppsala University"]